

FCDS Florida Cancer Data System




2016 FCDS Lung Audits

(DX = 2014 or 2015)

1

**FCDS ANNUAL CONFERENCE
ORLANDO, FLORIDA
7/27/2016**

**STEVEN PEACE, CTR
MEG HERNA, CTR**





CDC & Florida DOH Attribution

2

FCDS

“We acknowledge the Centers for Disease Control and Prevention, for its support of the Florida Cancer Data System, and the printing and distribution of the materials for the 2015-2016 FCDS Webcast Series under cooperative agreement DP003872-03 awarded to the Florida Department of Health. The findings and conclusions in this series are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention”.



FCDS would also like to acknowledge the Florida Department of Health for its support of the Florida Cancer Data System, including the development, printing and distribution of materials for the 2015-2016 FCDS Webcast Series under state contract CODJU. The findings and conclusions in this series are those of the author(s) and do not necessarily represent the official position of the Florida Department of Health.

Presentation Outline

3

- 2016 Audit Process - Lung
- 2014 Selected Facilities & Cases
- 2015 Selected Facilities & Cases
- Audit Summary Reports
- Audit Technical Summary Report
- FCDS Webcast - Lung Cancer Data Quality & Staging
- ACS National Great American Smokeout – Same Day as Webcast
- 2017 Audit Plan – Dx Year 2016 – Male Genitourinary System ?



2016 Audit Process

4

FCDS DATA VALIDATION AUDIT with E-PATH VERIFICATION
11/1/2016

FCDS DATA VALIDATION AUDIT with E-PATH VERIFICATION

Diagnosis Year: 2014 or 2015

Cancer Site: Lung

Hospital Analytic Cases Only

Facilities: Appendix A

TABLE OF CONTENTS

Preface	Page
Table of Contents	4
List of Abbreviations	5
1 Background	6
2 Objectives	7
3 Eligibility	7
4 Study Design	7
5 Data Collection Procedures	9
6 Data Analysis	9
7 Quality Control/Quality Assurance	8
8 Regulatory Requirements	10
9 References	10
Appendices	12

3. ELIGIBILITY

- Facilities will be selected according to enhanced 5-year selection criteria as well as stratified by 2014 reporting year caseload for each primary site to be audited (primary lung cancer).
- A facility may be selected for more than 1 audit during the 5-year cycle using the enhanced facility select criteria.
- Case Selection will be based upon the following criteria:
 - o Date of Diagnosis 01/01/2014-12/31/2014 or Date of Diagnosis 01/01/2015-12/31/2015
 - o Primary Site = C34.0-C34.9 (Lung)
 - o Behavior = 1 (in-situ) or 3 (malignant)
 - o Central Sequence = 00 (only 1 cancer ever reported)
 - o ICD-O-3 Histology Not = 9590-9992 (no lymphoma, leukemia, or other hematopoietic malignancy)
 - o Class of Case = 10, 11, 12, 13, 14, 20, 21, 22 (hospital analytic – diagnosed and/or treated at facility)
- Case Selection will stratified by 2014 or 2015 reporting year caseload for primary lung cancer from calendar year 2014 or 2015 diagnoses.
- Pathology Selection will be based on any e-pathology report(s) with Date of Specimen within 30 days of the original Date of Diagnosis (plus or minus 30 days) as documented coded on the original case abstract.

2015 Selected Facilities & Cases

7

Re-Abstract Audit Status

Year: 2015

Beginning Facility: 1100-SHANDS UNIVERSITY OF FLORIDA

Ending Facility: 7448-FLORIDA HOSPITAL MEMORIAL MED CTR

Contractor: Both

Total: 935
UnMatched: 935

Export to Excel
Complete Facilities

Facility	Master Records		Incomplete		Complete		Facility		FCDS	
	Abstract	Path	Abstract	Path	Abstract	Path	To Do	Compl	Reco	Reconcile
1100-SHANDS	22	11	0	0	0	0	0	0	0	0
1308-...	9	1	0	0	0	0	0	0	0	0
...	13	3	0	0	0	0	0	0	0	0
...	9	9	0	0	0	0	0	0	0	0
...	10	5	0	0	0	0	0	0	0	0
...	3	2	0	0	0	0	0	0	0	0
...	9	1	0	0	0	0	0	0	0	0
...	9	2	0	0	0	0	0	0	0	0
...	9	3	0	0	0	0	0	0	0	0
...	9	6	0	0	0	0	0	0	0	0
...	9	5	0	0	0	0	0	0	0	0
...	9	3	0	0	0	0	0	0	0	0
...	9	3	0	0	0	0	0	0	0	0
...	8	5	0	0	0	0	0	0	0	0
...	9	8	0	0	0	0	0	0	0	0
...	6	5	0	0	0	0	0	0	0	0
...	6	5	0	0	0	0	0	0	0	0
Facility Count: 68	627	308								

68 facilities
627 total records
308 e-path records

Audit Summary Reports

8

Final Reabstract Summary Report
For Audit Year: 2015
Facilities: 1100-7448

Reabstract Summary Report - Insufficient Text
For Audit Year: 2015
Facilities: 1100-7448

Reabstract Summary Report - Coding Errors
For Audit Year: 2015
Facilities: 1100-7448

Prepared for STEVE PEACE on 5/11/2017 11:19:05 AM

Prepared for STEVE PEACE on 5/11/2017 12:14:54 PM

Prepared for STEVE PEACE on 5/11/2017 12:15:42 PM

Audit Summary Reports

9

FCDS 2016 Data Validation and E-Pathology ReAbstract Audit Report Key (Major, Minor and Text Errors Defined By Section of Audit Report)		
Major Error	Minor Error	Text Error
Major Errors are errors that may result in significant changes to the case or may alter core data or key information on the case	Minor Errors are errors that will not result in significant changes to the case or will not alter core data/key information on a case	Text Errors are errors found in recoding data from original text, only. The original text resulted in minor coding or other error that was later resolved at time of facility reconciliation when text was provided after-the-fact
<i>Example: Date of Diagnosis after final reconciliation was different by more than 1 month</i>	<i>Example: Date of Diagnosis after final reconciliation was different by less than 30 days</i>	<i>Example: There was no text documentation to identify the correct Date of Diagnosis – However, at the time of facility reconciliation sufficient text was provided to verify the dx date</i>
Case Diagnosis Data Items		
Date of Dx > 1 month	Date of Dx < 1 month	Any Tumor Item Noted as - Text
Laterality	Primary Sub Site Code	(Indicates text incomplete)
Morphology	Grade Value	
Behavior		
Stage at Diagnosis and Stage-Related Data Items		
CS Tumor Size/Extension	Tumor Size Value	Any Stage Item Noted as - Text
CS Lymph Nodes	# Regional Nodes Positive	(Indicates text incomplete)
CS Mets at Dx	# Regional Nodes Examined	
	Any Site Specific Factor Code	

Audit Summary Reports

10

Total All Facilities						
Case Dx	Minor Discrepancy		Major Discrepancy		Total Discrepancies	
	Count (n=60)	Pct	Count (n=60)	Pct	Count (n=60)	Pct
Dx Date (dd)	60	9.71			60	9.71
Dx Date (mmyyyy)			28	4.53	28	4.53
Dx Date-Text	10	1.62			10	1.62
Primary Site (C99)			4	.65	4	.65
Primary Site-Text	6	.97			6	.97
Sub Site	56	9.06			56	9.06
Morphology ICDO3			56	9.06	56	9.06
Morphology ICDO3-Text	7	1.13			7	1.13
Grade	35	5.66			35	5.66
Grade-Text	4	.65			4	.65
Laterality			28	4.53	28	4.53
Laterality-Text	6	.97			6	.97
Total:	184		116		300	

Audit Summary Reports

11

Stage	Minor Discrepancy		Major Discrepancy		Total Discrepancies	
	Count (n=63)	Pct	Count (n=63)	Pct	Count (n=63)	Pct
Tumor Size	63	10.19			63	10.19
Tumor Size-Text	11	1.78			11	1.78
CS Extension			268	43.37	268	43.37
CS Extension-Text	15	2.43			15	2.43
Reg Node Positive			38	6.15	38	6.15
Reg Node Positive-Text	5	.81			5	.81
Reg Node Examined			45	7.28	45	7.28
Reg Node Examined-Text	9	1.46			9	1.46
CS Lymph Nodes			94	15.21	94	15.21
CS Lymph Nodes-Text	12	1.94			12	1.94
CS Mets at DX	158	25.57			158	25.57
CS Mets at DX-Text	5	.81			5	.81
SSF1	128	20.71			128	20.71
SSF1-Text	6	.97			6	.97
Total:	412		445		857	

Audit Summary Reports

12

Treatment	Minor Discrepancy		Major Discrepancy		Total Discrepancies	
	Count (n=27)	Pct	Count (n=27)	Pct	Count (n=27)	Pct
Surgical Treatment (Coding Diff)	27	4.37			27	4.37
Surgical Treatment (vs None)			4	.65	4	.65
Surgical Treatment-Text	4	.65			4	.65
Scope Surg (Coding Diff)	5	.81			5	.81
Scope Surg (vs None)			47	7.61	47	7.61
Scope Surg-Text	4	.65			4	.65
Radiation Treatment (Coding Diff)	15	2.43			15	2.43
Radiation Treatment (vs None)			15	2.43	15	2.43
Radiation Treatment-Text	10	1.62			10	1.62
Rad Rx Modality	42	6.80			42	6.80
Rad Rx Modality-Text	16	2.59			16	2.59
Chemo Treatment (Coding Diff)	14	2.27			14	2.27
Chemo Treatment (vs None)			31	5.02	31	5.02
Chemo Treatment-Text	12	1.94			12	1.94
Hormone Treatment (vs None)			2	.32	2	.32
Brm Therapy (vs None)			11	1.78	11	1.78
Total:	149		110		259	
	745		671		1416	

Audit Technical Summary Report

13

- FCDS always uses Abstractor Text Documentation during AUDITS over text from e-pathology-only because the registrar may not have had access to all of the e-pathology report(s) at the time of abstract.
- Then why include the e-pathology as a part of the audit?
- Any Facility or Reconciliation Case(s) that did not meet the Reconciliation Deadline were counted as errors due to No Response.
- Never Change Your Data Until the FINAL REPORTS are issued.
- Date of Diagnosis – Imaging versus Biopsy/Resection
- Primary Site vs. Mass of Mediastinal or Hilar Nodes on Imaging

Audit Technical Summary Report



14

- Clarify the Difference between Atelectasis, Obstructive Pneumonitis, Consolidation, and (Malignant/Non-Malignant) Pleural Effusion
 - Atelectasis/Pneumothorax = Complete or Partially Collapsed Lung
 - Pneumonitis - inflammation of the walls of the alveoli in the lungs, often caused by a virus.
 - Obstructive Pneumonitis – pneumonitis resulting in bronchial obstruction
 - Consolidation - a region of lung tissue that has filled with liquid or blood or pus instead of air
 - Pleural Effusion/Hemothorax - a buildup of extra fluid in the space between the lungs and the chest wall.
 - ✦ Most pleural effusions are hemorrhagic or bloody which indicates malignant pleural effusion without even looking at cytology
 - ✦ Any pleural effusion in lung cancer is deemed “malignant” and must be proven “negative” x 2-3 cytology examinations
 - ✦ When pleural effusion described as “minimal” or “small” it may not be ‘treated’ as with involvement – still code as malignant pleural effusion for consistency in staging cases
 - Primary Tumor Extension to either Pleura is not the same as pleural effusion

Audit Technical Summary Report

15

- Tumor Size 000 (no evidence of primary tumor) vs. 999 (unk)
- Several Regional Lymph Node Issues
 - N1, N2 and N3 are ALL “regional lymph nodes”



- Must look at whether hilar or mediastinal nodes – do not treat as same
- Coding FNA of Regional Lymph Node in Scope of Reg Lymph Node Surgery
- Coding Regional Lymph Nodes Examined / Regional Lymph Nodes Positive
- Disconnect between Surgery of Primary Site Code 30 versus 33 and “regional” node definitions – often code 33 is for mediastinal node removal

Audit Packet & Facility Reports


16

- Audit Packet Includes:
 - Audit Cover Letter
 - Audit Technical Summary Report – Audit Findings
 - Audit Report Key
 - Final Reabstract Summary Report – Data Tables
 - Reabstract Summary Report - Insufficient Text
 - Reabstract Summary Report – Coding Errors Only
- Facility Reports via FCDS IDEA (HOSPADMIN)
 - Confidential Reports for Your Facility Only
 - Your Facility Summary Reports – compare to audit summary
 - Individual Case Reports with Reconciliation Documentation

Webcast: Lung Cancer Data Quality & Staging

17


- FCDS Webcast on **11/16/2017**
- Lung Cancer Facts
- FCDS Audit Findings
- FCDS Audit Recommendations
- Review of Lung Anatomy for Staging
- Review of Lung Cancer Staging Issues
 - SS2000 and SS2018
 - AJCC 7th edition
 - AJCC 8th edition
 - SSFs - Site Specific Items Required for Staging
- Staging & Site Specific Items - Practice Cases
- Latest Research
- Q&A



2017 Audit Plan

18

- Genitourinary System
 - Kidney
 - Bladder
 - Prostate
- 2016 Diagnosis Year
- Analytic Cases Only
- ~65 Facilities
- ~500 cases
- Sample will include free-standing radiation therapy centers
- FOCUS: Grade Rules, MPH Rules, Staging, Treatment



Questions

19

